The short answer
Follow-up after differentiated thyroid cancer is built on two moving numbers, thyroglobulin and TSH, plus a lifelong tablet. This page explains what each one is doing, what radioactive iodine can leave behind years later, and why medullary thyroid cancer turns follow-up into a family matter.
NCI states that a raised serum thyroglobulin correlates strongly with recurrent tumor after treatment for differentiated thyroid cancer.
Thyroglobulin is most sensitive when the person is hypothyroid and TSH is elevated, which is why the timing of the blood draw matters.
After thyroidectomy, supratherapeutic thyroid hormone is routinely given to suppress TSH; NCI says this improves progression-free survival but has no definitive overall survival benefit.
NCI lists second malignancies, sialadenitis and lacrimal and salivary gland dysfunction as long-term complications of radioactive iodine.
Choose how you want to understand this
The full explanation.
Follow-up here has an unusual shape
Most cancer follow-up watches for symptoms and repeats scans. Differentiated thyroid cancer adds two things. A blood protein that should be almost absent. And a hormone held below normal on purpose.
Understanding those two numbers explains most of what happens at the appointments.
Thyroglobulin, and why timing changes the answer
Thyroglobulin is made by thyroid tissue and by nothing else. Take out the gland, destroy what is left, and there should be very little source for it.
NCI puts it plainly. A raised serum thyroglobulin correlates strongly with recurrent tumor after treatment for differentiated thyroid cancer. That is the whole logic of the test.
There is a catch in how it is drawn. NCI notes that levels are most sensitive when the person is hypothyroid, with a raised TSH. A result taken on a fully suppressed TSH is not the same test. So a low number is worth asking about, not just filing.
Radioactive iodine feeds into this too. NCI says its goal is to destroy the thyroid tissue left behind. That does two things. It makes the thyroglobulin test more specific. And it lets whole-body scanning pick up disease that persists. This is why near-total or total thyroidectomy is required when iodine is planned. A large remnant makes a low thyroglobulin impossible to reach.
The TSH target is low on purpose
Thyroid-stimulating hormone tells thyroid tissue to grow. That is exactly what nobody wants after a thyroid cancer.
NCI is direct about the consequence. After thyroid surgery, everyone except people who had a lobectomy needs hormone replacement. After a full thyroidectomy, higher-than-replacement doses are routinely given to push TSH down. How far down depends on recurrence risk. It also depends on the person's other conditions.
The evidence has a boundary worth knowing. NCI says studies suggest TSH suppression improves progression-free survival. It also says there is no definitive evidence that it improves overall survival. That is why the target is loosened for some people over time. It is a conversation, not a fixed number.
What radioactive iodine can leave behind
NCI lists three long-term complications of 131I:
- Second malignancies.
- Sialadenitis, meaning inflammation of a salivary gland.
- Lacrimal and salivary gland dysfunction.
Dry mouth, taste change and a blocked tear duct are what those last two feel like in daily life. They are a reason to know whether the iodine was necessary in the first place.
The dose question in low-risk disease
Two phase III noninferiority trials compared 1.1 GBq (30 mCi) with 3.7 GBq (100 mCi) in low-risk disease. Both also compared two ways of raising TSH. One was stopping thyroid hormone. The other was an injection of recombinant human thyrotropin.
Ablation rates were equivalent at 6 to 10 months. Complete ablation reached 92% in the more tightly selected group. People who went through hormone withdrawal had more hypothyroid symptoms. Their quality of life was worse than in the rhTSH group.
NCI adds two honest limits. Neither study assessed the effect of low-dose iodine on long-term recurrence or survival. Neither addressed whether iodine could be safely left out altogether in specific low-risk groups.
One retrospective series followed 1,298 patients with small, node-negative tumors for 10.3 years. Of those, 911 had iodine after surgery and 387 did not. Multivariate analysis found no difference in overall survival. It found none in disease-free survival either.
Calcium and voice after neck surgery
Four parathyroid glands sit next to the thyroid, each about the size of a pea. NCI describes their job as controlling the amount of calcium in the blood. They sit in the surgical field. That is why blood chemistry measuring calcium appears in NCI's list of tests here.
Hoarseness appears on NCI's list of thyroid cancer signs. Laryngoscopy is on its list of tests. That means looking at the voice box, with a mirror or a scope. A voice that has not recovered is worth naming at follow-up rather than waiting out.
When the cancer was medullary
Medullary thyroid cancer is a different disease inside the same gland. NCI describes it as a neuroendocrine tumor arising in the C cells, which make calcitonin, a hormone that helps keep blood calcium at a healthy level.
It can also be inherited. NCI names three genetic conditions here. Familial medullary thyroid cancer. Multiple endocrine neoplasia type 2A. Type 2B. An inherited change in the RET gene can cause it. A genetic test exists, and NCI describes the order plainly. The patient is tested first. If the changed gene is there, other relatives may be tested. Relatives who carry it, including young children, may have a thyroidectomy to lower the chance of the cancer developing.
That makes medullary follow-up a family matter in a way that papillary and follicular cancer usually are not.
The numbers behind the reassurance
The American Cancer Society projects 45,240 new thyroid cancers and 2,320 deaths in the United States in 2026. Of those diagnosed, 63% are localized. For people diagnosed between 2016 and 2022, SEER puts 5-year relative survival at that stage at 99.9%.
Staging also changed in a way that affects older records. The age cutoff for risk grouping in well-differentiated thyroid cancer moved from 45 years to 55. That happened in the 8th edition of the AJCC manual. A stage assigned under the older edition is not directly comparable to one assigned now.
For the broader picture of life after treatment, see survivorship and watching for recurrence.
Where this comes from
Words to know
Tap any term to see what it means.
Common questions
What is thyroglobulin actually measuring?
Thyroglobulin is a protein made by thyroid tissue. Once the thyroid has been removed and any remnant ablated, there should be very little left to make it. NCI says an elevated level correlates strongly with recurrent tumor during postoperative evaluation.
Why is my TSH kept below normal on purpose?
Thyroid-stimulating hormone drives thyroid tissue to grow. After thyroidectomy, NCI says supratherapeutic doses of thyroid hormone are routinely given to suppress TSH. How far it is suppressed depends on recurrence risk and other health conditions.
Does radioactive iodine have long-term effects?
NCI lists three: second malignancies, sialadenitis, and lacrimal and salivary gland dysfunction. Those are reasons to weigh whether a dose is needed, and how large it should be.
Was radioactive iodine necessary at all?
For low-risk disease that is an open question. In one series of 1,298 patients followed for 10.3 years, 911 received radioactive iodine after surgery and 387 did not, and multivariate analysis found no difference in overall or disease-free survival.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Your next step
Turn this topic into questions for your next appointment.
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Sources last checked: 2026-08-16 what this meansLast updated: 2026-08-17Next planned review: 2028-07-30
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
- What Is Thyroid Cancer? Types and Signs
- Cancer Staging: What the Stage Means
- Biomarker Testing and Precision Medicine
- Getting a Second Opinion After a Diagnosis
- Questions to Ask About Thyroid Cancer Treatment
- Thyroid Cancer Recurrence: What to Ask
- Metastatic Thyroid Cancer: What to Ask
- Cancer Survivorship and Life After Treatment
Still have questions?
Educational answers, plain language
Free to print and share